Overview
Employees
51-200 employees
Category
Next Generation Immuno-Oncology Therapeutics
Apogenix develops innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. The company has built a promising pipeline of drug candidates that target different TNFSF-dependent signaling pathways, thereby restoring the anti-tumor immune response. Since its inception in fall 2005, Apogenix has raised more than 90 million euros in financing rounds, public grants, as well as upfront and milestone payments from licensing agreements. The company is based in Heidelberg, Germany. Apogenix’ lead drug candidate APG101 is a fully human fusion protein that consists of the extracellular domain of the CD95 receptor and the Fc domain of an IgG antibody. The substance inhibits the CD95 ligand which plays an important role in the progression of solid tumors. Depending on the target cell – immune cell or tumor cell – the interaction between the CD95 ligand and the CD95 receptor induces either apoptotic cell death or invasive growth of cells. With this unique dual mode of action, APG101 is being developed for the treatment of solid tumors and malignant hematological diseases. So far, the substance has been successfully evaluated in clinical trials for the treatment of glioblastoma and myelodysplastic syndromes (MDS). Better than antibodies – Apogenix’ HERA-ligand technology: Apogenix’ proprietary HERA-ligand technology platform enables the construction of novel hexavalent TNFSF receptor agonists for the treatment of cancer. Preclinical experiments have shown that these agonists effectively stimulate the immune system, marking them as promising candidates for the treatment of solid tumors.
